Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

LIXT earnings analysis

Filed May 14, 2026 · Our reading of the company's report

The latest report

Lixte Biotechnology Holdings, Inc. has not yet realized revenue and continued to incur significant losses with a net loss of $1,987,608 for Q1 2026, up from a net loss of $709,555 in Q1 2025. The company is engaged in…

Read full summary

Lixte Biotechnology Holdings, Inc. has not yet realized revenue and continued to incur significant losses with a net loss of $1,987,608 for Q1 2026, up from a net loss of $709,555 in Q1 2025. The company is engaged in early-stage clinical trials and reports substantial management and development costs. There are significant concerns regarding the company's ability to continue as a going concern over the next 12 months due to the lack of capital and revenue generation.

Read the original on SEC.gov

Reported figures

Earnings per share
$-0.18

What stood out

  • No Revenue Generation

    Lixte reported no revenue for the three months ended March 31, 2026, consistent with zero revenue from the same period in 2025.

  • Net Loss Increases

    The net loss for Q1 2026 was $1,987,608, significantly higher than the $709,555 net loss in Q1 2025.

  • R&D Costs Surge

    Research and development costs increased to $333,376 from $91,457 in the previous year, a 265% increase.

  • G&A Costs Spike

    General and administrative expenses rose to $1,654,031, compared to $615,483 in Q1 2025, an increase of 169%.

  • Cash Decrease

    Cash decreased by $1,856,222 during the quarter, with $3,250,650 cash remaining as of March 31, 2026.

  • Working Capital Decline

    The company's working capital decreased to $2,182,816 from $3,845,268 at the end of 2025.

What to watch

  • Substantial Doubt on Going Concern

    Management concluded there is substantial doubt regarding the company's ability to continue as a going concern for at least 12 months after the report date.

  • Reliance on Equity Financing

    The company is heavily dependent on periodic access to equity capital, increasing financial instability risk.

  • Adverse Clinical Trial Events

    Recent SAEs in clinical trials raised concerns which could lead to trial holds, affecting future development plans.

Management's outlook

Outlook deferred to earnings press release / call.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.